Sitravatinib Combination Therapy for Solid Cancers

Recruiting in Palo Alto (17 mi)

+25 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Mirati Therapeutics Inc.

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

Eligibility Criteria

This trial is for patients already benefiting from Sitravatinib alone or with other cancer drugs in a previous study, without severe side effects or another life-threatening illness. The doctor must believe continuing treatment is good for the patient.

Inclusion Criteria

You are currently taking sitravatinib alone or with other medications in another study sponsored by Mirati.

Currently tolerating the treatment regimen in the parent protocol

You are currently receiving treatment that is helping you, and your doctor thinks it's best to continue this treatment.

Exclusion Criteria

I may have another type of cancer besides the one being treated.

I do not have any severe illnesses that could affect my safety in the study.

Participant Groups

The study tests if Sitravatinib, on its own or combined with drugs like Ipilimumab, Nivolumab, Pembrolizumab, and Enfortumab Vedotin-Ejfv helps advanced solid tumors. It's for those who saw benefits in an earlier Mirati-sponsored trial.

1Treatment groups

Experimental Treatment

Group I: Phase 2/3: Open label extension of parent studyExperimental Treatment5 Interventions

The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.